Focusing on Gliomas: NCT01502917, a phase 1 clinical trial tested the safety and efficacy of 124I-omburtamab, a monoclonal antibody labeled with 124I targeting CD276 delivered by convection-enhanced delivery (CED) in patients with diffuse intrinsic pontine glioma (DIPG). Here, CD276 is linked to diffuse intrinsic pontine glioma.